Spots Global Cancer Trial Database for Pan-canceR Early DetectIon projeCT (PREDICT)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pan-canceR Early DetectIon projeCT (PREDICT)
Official Title: A Prospective, Multicenter Study on Development and Validation of the Performance of a cfDNA Methylation-based Model for Early Cancer Detection (Pan-canceR Early DetectIon projeCT, PREDICT Study)
Study ID: NCT04817306
Conditions
Interventions
Study Description
Brief Summary: PREDICT is a prospective, multicenter study for the early detection of pan-cancer through cell-free DNA (cfDNA) methylation-based model, in which approximately 14,000 participants will be enrolled. The development and validation of the model will be conducted in participants with cancers or benign diseases, along with non-tumor (healthy) individuals through a two-stage approach. The sensitivity and specificity of the model in cancer early detection will be evaluated, and the accuracy of the identification for tissue of origin will be obtained.
Detailed Description:
Eligibility
Minimum Age: 40 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Cancer Hospital, Chinese Academy of Medical Sciences & China National Cancer Center, Beijing, Beijing, China
Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, Shanghai, China
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Contact Details
Name: Jia Fan, M.D., Ph.D
Affiliation: Shanghai Zhongshan Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
